NeuroPace’s flagship product, the RNS System, is a closed‑loop, brain‑responsive neurostimulation device designed to detect seizure onset and deliver targeted stimulation to prevent seizures. The system continuously monitors and records EEG data, allowing physicians to personalize therapy and optimize care. Published data report an 82% median seizure reduction at three or more years, along with sustained improvements in quality of life and cognition. The RNS System is the only FDA‑approved brain‑responsive neurostimulator for focal onset refractory epilepsy, is available at most comprehensive epilepsy centers in the U.S., and is widely covered by insurance. NeuroPace says it has a robust product innovation pipeline and is pursuing expanded indications, including a planned clinical trial to extend use to patients under 18. The company recently raised $67 million to accelerate commercial growth, support market expansion, and fund clinical and product initiatives. NeuroPace’s core product is the RNS System, the first and only closed-loop brain‑responsive neurostimulation device FDA‑approved to treat adults with partial (focal) onset seizures not controlled by medication. The implanted system continuously monitors brain waves, detects unusual activity, and responds with imperceptible electrical pulses; physicians can non‑invasively program detection and stimulation parameters to personalize therapy. Clinical studies show long‑lasting outcomes, including a 72% median seizure reduction seven years after therapy initiation and about 30% of patients experiencing reductions of 90% or greater. Approximately 1,300 patients in the U.S. have been implanted with the RNS System to date, and the device also captures chronic EEG data that clinicians can use to improve outcomes. The company says the technology has potential beyond epilepsy to other disabling neurological disorders. NeuroPace recently closed new financing to accelerate commercialization and expand patient access to RNS Therapy.

Total raised

$141M

Funding rounds

3

Latest round

Equity

Latest activity

Aug 2020